Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects, according to the company. The poster, entitled "Generation of an antitumor response and immunity using a small molecule drug (PV-10)," was presented by Dr. Craig Dees, PhD, CEO and Savannah Blair of Provectus and authored by Dr. Dees along with co-authors S. Blair, J. Harkins, T.C. Scott, and E.A. Wachter. Data were analyzed by tumor (injected tumor, uninjected tumor, and total tumor burden) for time to progression and for tumor growth. PV-10 alone was favorable to saline control in all categories, while PV-10 combination therapy produced highly significant advantage versus control for time to progression of treated tumors (p = 0.010), untreated tumors (p = 0.011), and total tumor burden (p = 0.004).